Navigation Links
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis

age in Germany has actinic keratosis, the incidence doubles every 10 years. We will develop the 10 % formulation further for the treatment of this unusually frequent disease and intend to bring it to registration by 2009," commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG.

About Biofrontera AG Biofrontera AG is specialized in the development of pharmaceutical products in the area of dermatology. The company is characterized by a broad, relatively close to the market product portfolio and a solid liquidity. Biofrontera is listed in the regulated market of the Düsseldorf stock exchange under the symbol B8F and the ISIN number DE0006046113. http://www.biofrontera.com/

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.

For further information please contact:

Anke zur Mühlen Corporate Communication

+ 49 (0) 214 87632 22 + 49 (0) 214 87632 90 a.zurmuehlen@biofrontera.com

Biofrontera AG Hemmelrather Weg 201 D- 51377 Leverkusen, Germany


'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:9/2/2014)... DALLAS , September 2, 2014 ... Chromatography Column Market by Type (Empty, Pre-packed, Analytical, Preparative), by Material ... Flash Chromatography, UFLC), TLC,SFC] - Forecast to 2018", published by ... Million in 2013. It is poised to grow at ... Million by 2018. Browse 90 market ...
(Date:9/2/2014)... 2014 Particle Sciences, the leading CDMO for ... development and manufacturing capabilities with the addition of a ... Particle Sciences, Associate Director Clinical Production, "The company has ... square footage, equipment and staff across the board, all ... has over 6000ft 2 of operating cleanroom and ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® ... Alpine™ Hip Stem, the latest addition to its ... Stem is intended for use in total hip ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was ... stem philosophy. ODEV,s engineers worked closely with a ...
Breaking Medicine Technology:Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Ortho Development Receives FDA Clearance for Alpine Hip Stem 2
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
(Date:9/2/2014)... 2014 Today, Therapy Changes ... for Me?” The guide outlines common questions an individual ... addition to common types of groups an individual can ... from the interventions of the therapist, but also from ... group members,” says Rochelle Perper, Ph.D. and founder of ...
(Date:9/2/2014)... 02, 2014 The exciting information sessions ... professionals Carey Lewis and Bob Wiley. The ... those who have the desire to illuminate entertainment with ... performers could be invited to join the Bridge ... NC – Saturday, Sept. 6, Charlotte Convention Center, 501 ...
(Date:9/2/2014)... Las Vegas, NV (PRWEB) September 02, 2014 ... a leading provider of “Cloud Based” Medical Practice Business ... and a provider of Digital Cyber Security solutions for ... was recently interviewed on the trading floor of the ... Flynn. Mr. DeLaGarza stated that we are very ...
(Date:9/2/2014)... 02, 2014 On August 30, 2014, ... titled “Why You Should Wash Your Face .” ... the global population breathes air considered polluted by the ... lodge in the skin’s pores destroying its natural oils. ... free radicals that may cause cell damage, redness, ...
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3
... written about health care disparities between Latinos and non-Latino whites, ... same disparities from the perspective of the patient, in terms ... But how do the physicians feel about ... face in treating Latino patients, compared with physicians whose patients ...
... by helicopter, an expensive choice that may not impact patient ... and time is of the essence, helicopter transport is generally ... ground ambulance, but a paper published today in the online ... that the actual times to treatment for patients transported by ...
... HealthDay Reporter , WEDNESDAY, Oct. 12 (HealthDay ... for patients with a condition known as Barrett,s esophagus ... a large new Danish study suggests. Analyzing records ... determined that those with Barrett,s esophagus -- a disorder ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. 12 ... marijuana run more than twice the risk of crashing compared to ... if the driver has also been drinking alcohol. The ... Reviews believe the findings are especially relevant in light of ...
... , WEDNESDAY, Oct. 12 (HealthDay News) -- Black ... colon cancer have worse overall and recurrence-free survival rates than ... from nearly 15,000 black and white colorectal cancer surgery patients ... America between 1977 and 2002. All the patients received the ...
... WEDNESDAY, Oct. 12 (HealthDay News) -- The death toll from ... risen to 23, and a total of 116 people have ... Control and Prevention reported late Wednesday. The agency said ... 14, more cases might still emerge since Listeria monocytogenes ...
Cached Medicine News:Health News:Physicians treating Latinos have high hurdles to jump, study shows 2Health News:Interfacility helicopter ambulance transport of neurosurgical patients 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 3Health News:Pot Smoking May More Than Double Crash Risk 2Health News:Pot Smoking May More Than Double Crash Risk 3Health News:Blacks Fare Worse Than Whites After Colon Cancer Surgery 2Health News:Death Toll From Cantaloupe-Linked Listeria Outbreak Now Stands at 23 2
... Lyra-i system combines the longest available wavelength ... maximize patient safety and efficacy. The unique ... the therapeutic range to all targeted structures. ... ensuring patient safety. All Lyra-I patients are ...
... The Company's Aura-i Laser System is ... designed for office-based procedures. Its unique, integrated ... benign vascular, including telangiectasia on the leg ... leg veins. It can also be used ...
Surgisis Inguinal Hernia Matrix is implanted to reinforce soft tissues in the inguinal floor to repair inguinal hernias. Supplied sterile in peel-open packages. Intended for one-time use....
Used for implantation to reinforce soft tissue in the repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: